Abstract | OBJECTIVE: SUBJECTS AND METHODS: We investigated 31 eyes of 30 patients who had been given intravitreal pegaptanib sodium (0.3 mg) injections for subfoveal or juxtafoveal myopic CNV at 6-week intervals from July through December 2009. We compared visual acuity, retinal sensitivity within the central 12 degrees and maximum lesion diameter, and quantified metamorphopsia using M-CHARTS (Inami Co., Tokyo) both before and after the intravitreal injections. The Wilcoxon test was applied to identify statistically significant differences. RESULTS: Mean logMAR visual acuity was 0.49 +/- 0.38 before and 0.47 +/- 0.35 after treatment (p = 0.56); the corresponding values for mean retinal sensitivity were 7.48 +/- 3.69 dB and 8.15 +/- 4.18 dB (p = 0.24). Mean maximum lesion diameter was significantly reduced from 1,217 microm to 1,041 microm after treatment (p = 0.0021). Mean metamorphopsia scores were significantly improved after treatment, i.e., 0.85 +/- 0.68 to 0.50 +/- 0.39 for vertical lines (p = 0.016); 0.81 +/- 0.74 to 0.47 +/- 0.41 for horizontal lines (p = 0.017). The average number of injections was 3.1. No patient experienced adverse events associated with treatment. CONCLUSION:
|
Authors | Takako Kitagawa, Mitsuko Yuzawa |
Journal | Nippon Ganka Gakkai zasshi
(Nippon Ganka Gakkai Zasshi)
Vol. 117
Issue 4
Pg. 344-50
(Apr 2013)
ISSN: 0029-0203 [Print] Japan |
PMID | 23767190
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Aptamers, Nucleotide
- pegaptanib
|
Topics |
- Adult
- Aged
- Aptamers, Nucleotide
(administration & dosage, therapeutic use)
- Choroidal Neovascularization
(diagnosis, drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Myopia, Degenerative
(diagnosis, drug therapy)
- Pilot Projects
- Prospective Studies
- Retinal Vessels
(drug effects, pathology)
- Treatment Outcome
|